Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study-Reference-Cited by-同舟云学术

Bimonthly, treat‐and‐extend and as‐needed ranibizumab in naïve neovascular age‐related macular degeneration patients: 12‐month outcomes of a randomized study

Published:2020-03-19 Issue:7 Volume:98 Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

López Gálvez María Isabel¹^ORCID,Arias Barquet Lluís²,S. Figueroa Marta.³,García‐Layana Alfredo⁴,Ruiz Moreno José M.⁵,Fernandez Rodríguez Maribel,García Arumí Josep,Amat Peral Pedro,Ascaso Puyuelo Javier,Armada Maresca Félix,Cervera Taulet Enrique,Torres Imaz Ramón,Gutierrez Sánchez Estanislao,Cordovés Dorta Luis Mateo,Esteban González Eduardo,Velilla Osés Sara,Abengoechea Hernández Santiago,Ruiz Miguel Miguel,Basauri Rementería Erneesto,Caballos Castilla Rafael,Villavilla Castillo Jacinto,López Guajardo Lorenzo,Gallego Pinazo Roberto,Araiz Iribarren José Javier,Rodriguez García Laura,Cabrera López Francisco,López Garrido José Antonio,López‐Herrera María Lafuente,Alforja Castiella María Socorro,Ruiz Moreno Óscar,Martinez Alday Nerea,Fernández‐Vega Sanz Álvaro,Garcia Campos José,

Affiliation:

1. Department of Ophthalmology Hospital Clínico Universitario de Valladolid Valladolid Spain

2. Department of Ophthalmology Hospital Universitari de Bellvitge L’Hospitalet de Llobregat Barcelona Spain

3. Department of Ophthalmology Hospital Universitario Ramón y Cajal Madrid Spain

4. Department of Ophthalmology Clínica Universidad de Navarra Pamplona Spain

5. Department of Ophthalmology Hospital Universitario Puerta de Hierro‐Majadahonda Madrid Spain

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.14399

Reference33 articles.

1. Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2

2. Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol

3. A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration

4. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

5. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-year efficacy and safety of different anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: a network meta-analysis of randomized controlled trials;Eye;2024-09-11

2. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis;BMJ Open Ophthalmology;2024-07

3. Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen;BMJ Open Ophthalmology;2023-08

4. Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis;Eye;2023-03-01

5. STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION;Retina;2023-03